Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes

Nephrology

Volumn 22, Issue 1, 2017, Pages 49-57

  Takahashi, Yuichi ^a   Ikezumi, Yohei ^a   Saitoh, Akihiko ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

adriamycin; nephropathic syndrome; proteinuria; Rituximab; SMPDL 3b

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN G; NEPHRIN; PODOCIN; RITUXIMAB; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE ACID LIKE 3B PROTEIN; SYNAPTOPODIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; PROTECTIVE AGENT; SYNPO PROTEIN, RAT;

ADRIAMYCIN-INDUCED NEPHROPATHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; URINARY EXCRETION; ANIMAL; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; KIDNEY DISEASES; METABOLISM; PATHOLOGY; TIME FACTOR; WISTAR RAT;

ANIMALS; B-LYMPHOCYTES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; KIDNEY DISEASES; MICROFILAMENT PROTEINS; PODOCYTES; PROTECTIVE AGENTS; PROTEINURIA; RATS, WISTAR; RITUXIMAB; SPHINGOMYELIN PHOSPHODIESTERASE; TIME FACTORS;

EID: 85006456812     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12737     Document Type: Article

References (28)

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362: 629–39.
2. Schulman SL, Kaiser BA, Polinsky MS, Srinivasan R, Baluarte HJ. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J. Pediatr. 1988; 113: 996–1001.
3. Lombel RM, Hodson EM, Gipson DS. Kidney Disease: Improving Global Outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr. Nephrol. 2013; 28: 409–14.
4. Iijima K, Sako M, Nozu K et al. Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014; 384 (9950): 1273–81.
5. Magnasco A, Ravani P, Edefonti A et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 2012; 23: 1117–24.
6. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am. J. Nephrol. 2014; 39: 322–30.
7. Kari JA, El-Morshedy SM, El-Desoky S, Alshaya HO, Rahim KA, Edrees BM. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr. Nephrol. 2011; 26: 733–7.
8. Prytuła A, Iijima K, Kamei K et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 2010; 25: 461–8.
9. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte specific antigen. J. Immunol. 1980; 125: 1678–85.
10. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176–82.
11. Wymann MP, Schneiter R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 2008; 9: 162–76.
12. Fornoni A, Sageshima J, Wei C et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 2011; 3: 85-46.
13. Ginevri F, Trivelli A, Mutti A et al. Progression of chronic adriamycin nephropathy in leukopenic rats. Nephron 1993; 63: 79–88.
14. Kawachi H, Koike H, Shimizu F. mAb 5-1-6 nephropathy and nephrin. Microsc. Res. Tech. 2002; 57: 236–40.
15. Kawachi H, Orikasa M, Matsui K et al. Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen. Clin. Exp. Immunol. 1992; 88: 399–404.
16. Kawachi H, Koike H, Kurihara H, Sakai T, Shimizu F. Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli. J. Am. Soc. Nephrol. 2003; 14: 46–56.
17. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006; 107: 1070–7.
18. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45.
19. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000; 6: 443–6.
20. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–8.
21. Taji H, Kagami Y, Okada Y et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn. J. Cancer Res. 1998; 89: 748–56.
22. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–52.
23. Merrill AH Jr. De novo sphingolipid biosynthesis: an necessary, but dangerous, pathway. J. Biol. Chem. 2002; 277: 25843–6.
24. Fornoni A, Merscher S, Kopp JB. Lipid biology of the podocyte–new perspectives offer new opportunities. Nat. Rev. Nephrol. 2004; 10: 379–88.
25. Chan AC. Rituximab's new therapeutic target: the podocyte actin cytoskeleton. Sci. Transl. Med. 2011; 3: 85-21.
26. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008; 22: 659–61.
27. Cravedi P, Ruggenenti P, Remuzzi G. Low-dose rituximab for posttransplant recurrent membranous nephropathy. Am. J. Transplant. 2010; 10: 1336.
28. Nakao T, Ushigome H, Kawai K et al. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation. Transplant. Proc. 2015; 47: 644–8.